Thursday, June 13, 2013: Finally! A ruling in Association for Molecular Pathology v. Myriad Genetics, Inc. et al. Biotechnology company Myriad Genetics claimed exclusive rights to patents for ovarian and breast cancer DNA that it had isolated and genetically altered.  However,… Read More ›